.jpeg)
2026-10-12 06:15:41
Zongertinib is an oral highly selective HER2 tyrosine kinase inhibitor for unresectable locally advanced or metastatic non-small-cell lung cancer with confirmed HER2/ERBB2 tyrosine kinase domain activating mutations. In Beamion LUNG-1, first-line ORR was about 76% and median PFS 14.4 months; active brain metastases had intracranial ORR about 47%. Previously treated cohorts showed ORR about 71% and median PFS 12.4 months. Main issues are diarrhea, rash, transaminase elevation, and vigilance for ILD and LVEF decline.
2026-10-10 07:13:01
In July 2026, FDA converted selpercatinib (Retevmo) for RET fusion locally advanced or metastatic solid tumors from accelerated to traditional approval, covering ages 2 and older. In LIBRETTO-001 non-lung/non-thyroid cohort ORR was 47% and median DOR 24.5 months; adults 12+ use 120 or 160mg twice daily by weight, younger children use BSA-based dosing, with ongoing monitoring of transaminases, blood pressure, QTc, thyroid, and pediatric growth plates.
2026-10-10 07:07:16
On October 8, 2026, FDA approved atezolizumab, including Tecentriq Hybreza subcutaneous formulation, with fluoropyrimidine and oxaliplatin for adjuvant treatment of resected stage III dMMR colon cancer. In ATOMIC, adding atezolizumab to mFOLFOX6 halved relapse/death risk versus chemotherapy alone. Monitor immune pneumonitis, hepatitis, colitis, endocrinopathies, and oxaliplatin neuropathy.
2026-10-09 05:43:21
On October 7, 2026, FDA approved tucatinib (Tukysa) 300mg twice daily with trastuzumab and pertuzumab for maintenance in adults with unresectable locally advanced or metastatic HER2-positive breast cancer who did not progress after THP induction. In HER2CLIMB-05, median PFS was 24.9 vs 16.3 months; monitor hepatotoxicity, diarrhea, serum creatinine, and embryo-fetal risk.
2026-10-08 07:21:15
Zenocutuzumab is an intravenous HER2×HER3 bispecific antibody for adults with confirmed NRG1 gene fusion across selected advanced solid tumors. FDA covers NSCLC, pancreatic adenocarcinoma, and cholangiocarcinoma after prior systemic progression; standard 750mg IV every 2 weeks. eNRGy supports ORR and duration, with monitoring for infusion reactions, diarrhea, left ventricular function, and embryo-fetal risk.
2026-09-29 06:25:46
Pemigatinib is an oral FGFR1/2/3 inhibitor for advanced FGFR2 fusion/rearrangement cholangiocarcinoma and selected FGFR1-rearranged myeloid/lymphoid neoplasms. Cholangiocarcinoma uses 13.5mg once daily, 14 days on and 7 days off; FIGHT-302 and FIGHT-202 support sequencing decisions, with serum phosphate and OCT ophthalmology monitoring.
2026-09-28 04:14:55
Dabrafenib (Tafinlar) is an oral BRAF inhibitor active only in tumors with a BRAF V600E/K mutation. This guide covers its mechanism, FDA-approved indications, adult and pediatric dosing, the evidence for combining it with trametinib, and practical management of adverse reactions.
2026-09-22 08:14:01
How binimetinib adds MEK1/2 blockade to encorafenib in BRAF V600E/K unresectable or metastatic melanoma, covering mechanism, response, resistance and monitoring.
2026-09-17 02:55:47
Adagrasib is an oral irreversible KRAS G12C inhibitor. NSCLC standard dosing is 600mg twice daily; manage diarrhea, nausea, hepatotoxicity, QTc prolongation, and ILD. Colorectal use with cetuximab is under re-evaluation after KRYSTAL-10 missed PFS/OS endpoints.
2026-09-14 03:36:10
Ceritinib is an oral ALK tyrosine kinase inhibitor for validated ALK-rearranged locally advanced or metastatic non-small cell lung cancer. Usual 450mg once daily with food, with active management of diarrhea, hepatotoxicity, hyperglycemia, and QT prolongation.
2026-09-14 03:09:28
Enzalutamide commonly causes fatigue, musculoskeletal pain, dizziness, and hot flashes, with attention also needed for hypertension, falls, fractures, seizure, PRES, and ischemic heart disease. This guide covers tiered management and red-flag symptoms.
2026-09-10 03:33:16
Tamoxifen is a long-established endocrine therapy for breast cancer. Long-term use requires awareness of venous thromboembolism and endometrial abnormalities. This article outlines key adverse effects and at-risk populations.
